QTREX CEO’s Latest Share Buy Signals Confidence as Shares Surge 104% in a Month.

Insider Buying Continues Amid Volatile Market Conditions Ben‑Noon Dagi Shahar, the CEO of QTREX QUANTUM LTD, added 18,181 shares on October 9, 2026, paying $1.67 per share – a slight premium to the closing price of $1.63. This purchase is part of the company’s management share‑purchase plan announced in June, underscoring a commitment to aligning executive interests with those of minority shareholders. The transaction comes after a string of large buy‑sides by Shahar over the past months, most notably the 550,000‑share purchase in late August and the 168,894‑share block in late September. The cumulative effect is a significant increase in Shahar’s post‑transaction ownership, now exceeding 3.6 million shares.

Implications for Investors and the Company’s Outlook The timing of this trade is telling. QTREX has posted a sharp 104 % monthly rally, and its 52‑week high of $3.85 is still within reach. A CEO buying at the current level suggests confidence in the company’s near‑term prospects, particularly as it advances clinical trials for its respiratory support device. From a risk perspective, the negative price‑earnings ratio and the recent 53 % weekly gain indicate volatility. Nevertheless, insider buying can act as a counter‑balance to market sentiment, which remains dampened with a sentiment score of –22 and a buzz intensity of 60.53 %. For investors, Shahar’s continued purchases may serve as a bullish signal, but they should weigh this against the company’s still‑unrealized profitability and the broader health‑care sector’s regulatory landscape.

A Profile of Ben‑Noon Dagi Shahar Shahar’s trading history reveals a pattern of strategic accumulation rather than opportunistic flipping. His first notable block in August involved a zero‑price purchase of 550,000 shares, a common exercise under the employee share‑option program. Subsequent buys—168,894 shares in September at $0.71 each and 18,181 shares in October—show a willingness to pay above the market price when it aligns with a management plan. Across the last six months, Shahar has bought roughly 1.4 million shares, increasing his stake by about 20 %. The consistency of these trades suggests a long‑term commitment to the company’s mission, rather than short‑term speculation.

Market Context and Forward‑Looking Signals QTREX’s health‑care focus and its pioneering respiratory technology position it at the intersection of clinical need and technological innovation. The company’s recent price surge, coupled with a high 52‑week volatility range, indicates a window of opportunity for value investors. Shahar’s recent purchase, made through an open‑market transaction under a management plan, may be interpreted as an endorsement of the company’s valuation trajectory. For savvy investors, monitoring subsequent insider activity, especially any potential sell‑side actions, will be crucial in assessing whether the company’s leadership remains confident in its growth path or begins to hedge against upcoming regulatory or commercial milestones.